*Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

†Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte

††San Francisco Oncology, San Francisco, CA

‡Department of Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY

§Department of Radiation Oncology, ICM, Montpellier Cancer Institute

#Department of Pathology, CHU Montpellier, Montpellier, France

∥Department of Medical Oncology, BC Cancer

∥∥Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

¶Department of Pathology, The University of Chicago, Chicago, IL

**Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York

§§Division of Medical Oncology & Hematology, Northwell Health Cancer Institute, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY

‡‡Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India

¶¶Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center

##Department of Pathology and Laboratory Medicine, McGovern Medical School, Houston, TX

C.F. and J.B. are co-corresponding authors.

J.A.B. and S.D.G. contributed equally.

Presented at the 2022 USCAP Meeting in Los Angeles on March 21, 2022.

Conflicts of Interest and Source of Funding: Supported by a research grant from the National Institutes of Health (NCI, CA124633 to C.A.F.) and Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748 (R.A.G and B.X.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: Christopher A. French, MD, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115 (e-mail: [email protected]).